Ukuphepha, imiphumela emibi, nokuningi
I-Xolair (omalizumab) iyimithi ejojelwayo esetshenziselwa ukuphatha ngokulinganisela kuya ku- asthma ye- allergen. Ingasetshenziswa kubantu abaneminyaka engu-12 nangaphezulu abangasenaso isifo se-asthma ezingalawuliwe naphezu kwemithi ejwayelekile yesifo se-asthma , njenge- steroids engatholakali .
Ama-injection anikezwa ehhovisi likadokotela njalo ngemva kwamasonto amabili kuya kwamane kuye ngokuthi isisindo somuntu nesisindo se-antigen (IgE) somzimba.
(Hlola ukubona ukuthi i-asthma yakho ilawulwa yini ngokuthatha ukuhlolwa kwesimo se-asthma.)
Yini Okuyiyona I-Xolair?
I-Xolair iyi-anti-IgE e-monoclonal anti-IgE ehlanganisa i-IgE egazini, evumela umzimba ukuba ususe. Isidakamizwa sikhiqizwa ngamagundane ngakho-ke siqukethe amaprotheni cishe angu-5% wegundane (akubonakali ukuthi ukungezwani komzimba amaprotheni kubangela izinkinga kubantu abathola i-Xolair).
Lokhu kuvimbela i-IgE ukuthi ingaxhunyiwe kumaseli amancane futhi ibophezele ekuveleleni, ekugcineni okuphumela ekukhululweni kwe- histamine namanye amakhemikhali. Yilezi zamakhemikhali ezibangela ukuwohloka kwesifo sofuba kanye nezinye izimpawu zokungena komzimba.
Isidakamizwa siboniswe ukunciphisa ukuhlasela kwe-asthma, ukuthuthukisa ikhwalithi jikelele yokuphila kubantu abane-asthma, futhi kunciphise i- corticosteroids edingekayo. Ngokuvamile, kungathatha izinyanga ezimbalwa zokujova kwe-Xolair ukuqala ukusebenza. Futhi imithi ingabiza kakhulu.
I-Xolair ayilona ukwelashwa kwezimpawu ze-asthma-kulindeleke ukuthi ibe nzima kakhulu ezinyangeni ezimbalwa ngemuva kokuthi ukwelashwa kwe-Xolair kumiswe.
Ingabe Ukuthatha I-Xolair Ingozi?
I-Xolair manje inesixwayiso "sebhokisi elimnyama", okuyisitatimende sokuqapha esinikezwe imithi yi-US Food and Drug Administration (FDA). Lesi sixwayiso siphumelele ngenxa yemibiko yabantu ababhekene ne- anaphylaxis (ukusabela okwehlukile) ngemuva kokuthola i-Xolair.
Nakuba engekho imibiko ye-anaphylaxis ebulalayo ngenxa ye-Xolair, ezinye izimo ziye zazingathí sina futhi zingasongela ukuphila. Ngenxa yalesi sizathu, i-FDA idinga ukuthi abantu abathola i-Xolair bahlolwe ehhovisi labo odokotela isikhathi esithile ngemva kokujova kwabo. (Inani langempela lithathwa udokotela.)
Abantu abathola i-Xolair kufanele baqaphele izimpawu ezilandelayo ze-anaphylaxis, engaba khona amahora angu-24 (noma ngaphezulu) ngemva kokujova:
- Ukuphefumula, ukuphefumula, ukukhwehlela, ukuqina kwesifuba, noma ukuphefumula ukuphefumula
- Umfutho wegazi ophansi, ugozi, ukuphelelwa amandla, ukushaya kwenhliziyo okusheshayo noma okubuthakathaka
- Ukuqhuma, ukuhlambalaza, ukuvuthwa, noma ukuvuvukala
- Ukucabangela , ukuhlanza , uhudo , noma ubuhlungu besisu
- Ukuvuvukala komphimbo, ulimi, izindebe, noma amehlo
- Ukuqina okunamandla, izwi elihlabayo, inkinga yokugwinya
- Ukweqa okukhulu ngokuzumayo, impumulo enamandla egijima, noma ukuxubana komzimba
- Ukukhathazeka noma umuzwa wokwesaba
Uma kufanele kube khona noma iyiphi yalezi zimpawu, kubalulekile ukwazisa udokotela wakho ngokushesha. Odokotela abaningi banikeza iziguli ezine-injection epinephrine engasetshenziswa ukuze zisebenzise esimweni se-anaphylaxis amahora angu-24 ngemva kokujola kwe-Xolair.
Ingozi yeCanscer Increase
Phakathi nokuthuthukiswa komtholampilo, izinga lomdlavuza laliphakeme kakhulu kubantu abathola i-Xolair uma kuqhathaniswa nabantu abathola ama-placebo injection.
Izinhlobo ze-khansela ezibonwe kubantu abathola i-Xolair zihlanganisa umdlavuza webele, umdlavuza wesikhumba, nomdlavuza wesifo sofuba. Akukaziwa ukuthi yini engase yenzeke esikhathini esizayo yokusetshenziswa kwe-Xolair kubantu abajwayele ukuthola umdlavuza, njengabadala.
Nakuba kubonakala ukuthi i-Xolair inemiphumela emibi kakhulu, kufanele ikhunjulwe ukuthi i-anaphylaxis kanye nokwakhiwa komdlavuza kwenzeka kuphela ezinombalwa ezincane zeziguli. Akukaziwa ukuthi kungani lezi zemibala zikhona, nakuba izifundo ziqhubeka ukucacisa isizathu.
Kubalulekile ukuqaphela ukuthi i-asthma engalawuleki ingabangela izinkinga ezinzima, kuhlanganise nokufa.
Futhi imithi esetshenziselwa ukuhlaselwa yi-asthma, njenge-oral and injected corticosteroids, ibe nohlu olude lwemiphumela emibi esetshenziswa isikhathi eside. Ngakho-ke, kubalulekile ukuxoxa nodokotela wakho izingozi nezinzuzo zokuthatha i-Xolair ye-asthma engalawulwa ngemithi ejwayelekile yesifo se-asthma.
I-Xolair yezinye izimo zempilo
Ucwaningo oluningana luhlolisise ukuhlomula kwe-Xolair ekwelapheni i-idiopathic urticaria (i-hives) engapheliyo, noma i-CIU. Ucwaningo lwamuva luhlolisise iziguli ezingaphezu kuka-300 ezine-CIU ezazingenayo izimpawu naphezu kokuthatha ama-antihistamines.
Izihloko zenziwa i-Xolair ezinyangeni ezihlukahlukene njalo emavikini amane. Amaphesenti angu-40 abantu abathola i-Xolair ye-high-dose, kanti amaphesenti angu-22 abantu abathola i-dose-dose Xolair, banesinqumo esiphelele semifantu engakapheli amasonto amabili okwelashwa. Izimpawu zanda kancane ngemva kokuba i-Xolair ivaliwe, ngakho-ke kwakungenasibonakaliso sesikhathi eside. Ngo-Mashi 2014, i-FDA ivume ukusetshenziswa kwe-Xolair ye-CIU.